Aim: This study aims to investigate drug utilization patterns in the treatment of psoriasis (PsO) from 1 to 5 years in a real-life setting with Adalimumab (Ada), Etanercept (Eta), Ustekinumab (Ust), Golimumab (Gol), Ixekizumab (Ixe), Secukinumab (Sec) and Apremilast (Apr). Materials & methods: Data from an observational study were used to calculate adherence using the Proportion of Days Covered (PDC) method and persistence. Results & conclusion: Treatment adherence was found to be good for all the drugs studied across all years of analysis, while persistence was suboptimal, showing a marked decrease from the third year of study onward. In the treatment of PsO, greater attention needs to be paid to treatment persistence.

Plain language summary

This summary explains that when a patient follows their doctor's medication instructions and continues using the same medication over time to treat a condition like psoriasis, they can expect safer and more effective outcomes. This study examined these aspects to assess how different medications perform over the long term and to explore ways to improve their prescription. The findings highlight that the main issue is not so much in following instructions but in continuing to use the same medication throughout the treatment duration. Raising awareness among healthcare professionals about these issues is crucial to help patients maintain consistent therapy over time and improve their care pathway.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Samarasekera EJ, Neilson JM, Warren RB et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340–2346. doi:10.1038/jid.2013.149
Medline CASGoogle Scholar
2. Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly 2014;144:w13968. doi:10.4414/smw.2014.13968
MedlineGoogle Scholar
3. Dowlatshahi EA, Wakkee M, Arends LR et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542–1551. doi:10.1038/jid.2013.508
Medline CASGoogle Scholar
4. Kolios AG, Yawalkar N, Anliker M et al. Swiss S1 guidelines on the systemic treatment of psoriasis vulgaris. Dermatology 2016;232(4):385–406. doi:10.1159/000445681
MedlineGoogle Scholar
5. American Academy of Dermatology Work G, Menter A, Korman NJ et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174. doi:10.1016/j.jaad.2010.11.055
MedlineGoogle Scholar
6. Leonardi CL, Romiti R, Tebbey PW. Ten years on: the impact of biologics on the practice of dermatology. Dermatol Clin. 2015;33(1):111–125. doi:10.1016/j.det.2014.09.009
Medline CASGoogle Scholar
7. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis–results of two Phase III trials. New England J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
MedlineGoogle Scholar
8. Armstrong A, Fahrbach K, Leonardi C et al. Efficacy of bimekizumab and other biologics in moderate-to-severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther. (Heidelb) 2022;12(8):1777–1792. doi:10.1007/s13555-022-00760-8
MedlineGoogle Scholar
9. Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate-to-severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49. doi:10.1016/j.jaad.2015.03.049
Medline CASGoogle Scholar
10. Schwartz DM, Kanno Y, Villarino A et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi:10.1038/nrd.2017.201
Medline CASGoogle Scholar
11. Menter A, Gelfand JM, Connor C et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–1486. doi:10.1016/j.jaad.2020.02.044
Medline CASGoogle Scholar
12. Augustin M, Kleyn CE, Conrad C et al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35(1):123–134. doi:10.1111/jdv.16431
Medline CASGoogle Scholar
13. Ozkok Akbulut T, Topaloglu Demir F, Oguz Topal I et al. Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study. Int J Dermatol. 2021;60(9):1140–1147. doi:10.1111/ijd.15628
MedlineGoogle Scholar
14. Ismail N, Collins P, Rogers S et al. Drug survival of fumaric acid esters for psoriasis: a retrospective study. British J Dermatol. 2014;171(2):397–402. doi:10.1111/bjd.12849
Medline CASGoogle Scholar
15. Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13(7):848–853.
Medline CASGoogle Scholar
16. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value in Health 2008;11(1):44–47. doi:10.1111/j.1524-4733.2007.00213.x
MedlineGoogle Scholar
17. Gniadecki R, Kragballe K, Dam TN et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. British J Dermatol. 2011;164(5):1091–1096. doi:10.1111/j.1365-2133.2011.10213.x •• Persistence as an indicator of the effectiveness of therapies in psoriasis, the basis for the analysis conducted in this study.
Medline CASGoogle Scholar
18. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117–122. doi:10.15386/mpr-1201 • Explanation of the method for calculating treatment adherence, essential for interpreting the results obtained in this study.
MedlineGoogle Scholar
19. Vrijens B, De Geest S, Hughes DA et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi:10.1111/j.1365-2125.2012.04167.
MedlineGoogle Scholar
20. Leonardi C, Zhu B, Malatestinic WN et al. Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM MarketScan((R)) databases. Advan Ther. 2022;39(7):3214–3224. doi:10.1007/s12325-022-02155-9
Medline CASGoogle Scholar
21. Belinchon I, Rivera R, Blanch C et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adher. 2016;10:2357–2367. doi:10.2147/PPA.S117006
Medline CASGoogle Scholar
22. Doshi JA, Takeshita J, Pinto L et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057–65 e4. doi:10.1016/j.jaad.2016.01.048
MedlineGoogle Scholar
23. Huang YH, Tang CH, Goh CH et al. Persistence and adherence to biologics in patients with psoriasis in Taiwan: a new biologics user cohort study. Front Pharmacol. 2022;13:880985. doi:10.3389/fphar.2022.880985
Medline CASGoogle Scholar
24. Piragine E, Petri D, Martelli A et al. Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. J Clin Med. 2022;11(6):1506 doi:10.3390/jcm11061506 • A recent and in-depth review of adherence levels in psoriasis, a useful tool for comparing the data analyzed in this study.
Medline CASGoogle Scholar
25. Yiu ZZN, Becher G, Kirby B et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131–1141. doi:10.1001/jamadermatol.2022.2909
MedlineGoogle Scholar
26. Costanzo A, Malara G, Pelucchi C et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology 2018;234(1–2):1–12. doi:10.1159/000488586
MedlineGoogle Scholar
27. Torres T, Puig L, Vender R et al. Drug Survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579. doi:10.1007/s40257-021-00598-4 •• An interesting study that highlights how over time there is a proportional loss of persistence that deserves attention, especially in long-term treatments such as those prescribed for the treatment of psoriasis.
MedlineGoogle Scholar
28. Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068. doi:10.1038/s41598-018-34293-y •• A meta-analysis over a 4-year period, a useful comparison for this study with data on the medium to long term.
MedlineGoogle Scholar

Ahead of Print

Metrics

Downloaded 26 times

History

Received 14 April 2023

Accepted 22 September 2023

Published online 23 April 2024

Information

Keywords

Author contributions

Each authors contributed (a) to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (b) drafting the work or revising it critically for important intellectual content; AND (c) final approval of the version to be published; AND (d) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

All authors report no conflicts of interest, with the exception of Enrico Pasut, who provided consultancy services for Biogen in 2020. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download